Is DANOY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Health-focused portfolio and protein, with revenue (ttm) at ~€27.4 billion. The bear case rests on product-safety events are the most acute risk for a company that sells infant formula and medical nutrition, as the 2026 recall showed: the ADR fell ~8% on January 21 and ~2.7% more two days later. Analysts covering it are spread from $16.50 to $21.10, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Product-safety events are the most acute risk for a company that sells infant formula and medical nutrition, as the 2026 recall showed: the ADR fell ~8% on January 21 and ~2.7% more two days later. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $16.50, +19.6% from the $13.80 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Health-focused portfolio and protein. Danone has leaned its brands toward gut health, protein and medical nutrition, categories that have grown faster than packaged food overall as consumers, including users of GLP-1 weight-loss drugs, look for higher-protein foods. The most optimistic analyst target on DANOY is $21.10, +52.9% from the $13.80 price. That figure is only reachable if this thesis works close to its best case.

Product-safety events are the most acute risk for a company that sells infant formula and medical nutrition, as the 2026 recall showed: the ADR fell ~8% on January 21 and ~2.7% more two days later. Several US plaintiff firms, including Rosen and Pomerantz, then announced investigations on behalf of DANOY holders, although no filed securities class action had surfaced in public reporting as of this writing. China, a key market for formula and for Mizone water, faces a falling birth rate and a slower economy, while the Waters business is sensitive to weather, plastics regulation and scrutiny of mineral water treatment practices in France. Because DANOY is priced in dollars while Danone reports in euros, a stronger dollar lowers the ADR's value and its dividend even when the underlying business is unchanged, and currency already turned 2025's ~4.5% organic growth into a slight reported decline. Dividends are paid once a year and face French withholding tax (25% by default, reducible to the 15% treaty rate with paperwork), and the ADR trades over the counter with thinner volume and wider spreads than the Euronext Paris listing. The most pessimistic published target is $16.50, +19.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Paris-based food group selling dairy and plant-based products, specialized and infant nutrition and bottled water (Activia, Alpro, Aptamil, Evian).

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Health-focused portfolio and protein) stalling in the reported numbers rather than in the narrative, the risk above (product-safety events are the most acute risk for a company that sells infant formula and medical nutrition, as the 2026 recall showed: the ADR fell ~8% on January 21 and ~2.7% more two days later) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

DANOY is the ticker for Danone's sponsored American Depositary Receipt, which trades over the counter in the US. Danone itself is listed on Euronext Paris under the ticker BN, is part of the CAC 40 index, and reports in euros. The ADR lets US investors hold the company as a dollar-denominated security in an ordinary US brokerage account, without opening a foreign account or converting currency themselves. A depositary bank holds the underlying French shares and passes through dividends, net of depositary fees and French withholding tax. Because it trades OTC rather than on the NYSE or Nasdaq, Danone does not file full annual reports with the SEC the way a US-listed company does, and trading volume is lower, so bid-ask spreads can be wider than on the Paris listing. Many US brokers support it, including fractional purchases at some.

Each DANOY ADR represents one-fifth of one ordinary Danone share, so five ADRs equal one Paris-listed share. That is why the ADR closed at ~$13.63 on October 15, 2026 while the Paris share trades around ~€58 to €59. To compare the two, multiply the ADR price by five and convert at the current euro to dollar rate; small gaps between the two usually reflect timing and exchange-rate moves rather than a real mispricing, because arbitrage keeps them close. Per-share figures in Danone's reports need to be divided by five to get the per-ADR equivalent. For example, recurring EPS of ~€3.80 works out to ~€0.76 per ADR and the €2.25 dividend to ~€0.45 per ADR, before currency conversion. Price-based ratios such as the P/E are the same whichever line is used.

Danone sells three broad types of products. Essential Dairy and Plant-Based, its largest segment, includes Activia, Danone, Oikos, YoPRO, Silk, Alpro and International Delight coffee creamers. Specialized Nutrition covers infant formula such as Aptamil and Nutrilon and medical nutrition under Nutricia, including specialised feeds for hospital patients, people with allergies and older adults, and it carries the group's richest margins. Waters includes Evian, Volvic, Aqua in Indonesia and Mizone in China. Recent acquisitions such as Kate Farms, The Akkermansia Company and Huel extend the company further into protein shakes, gut-health supplements and complete nutrition. Geographically, Europe and North America are the largest regions, while China, Asia and Latin America supply a meaningful share of growth, particularly in formula and water.